DSGN

DSGN

Design Therapeutics Inc

Rev โ€”top 1%5Y
Hold

Design Therapeutics Inc develops small molecule therapeutic drugs for genetic diseases using its GeneTAC platform. Key candidates target Friedreich Ataxia, Myotonic Dystrophy Type-1, Fuchs Corneal Dystrophy, and Huntington's Disease.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$880today

Score Overview

1 Year
Scoreโ€”
Net Growth-1.44%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-99.24%
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-99.24%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Design Therapeutics Inc fundamental performance

Across Design Therapeutics Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 35M to -$ 69M. Revenue increased in 0% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 14.66โ€”
1 Year2025-08-12
$ 4.98194.38%
5 Years2021-08-12
$ 16.66-12.00%
All Time2021-03-26
$ 41.49-64.67%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 70M$ 207M
2025$ 0.00-$ 69M$ 219M
2024$ 0.00-$ 49M$ 245M
2023$ 0.00-$ 66M$ 281M
2022$ 0.00-$ 58M$ 330M
IPO2021$ 0.00-$ 35M$ 384M

Explore beyond DSGN

You're looking at Design Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies